CLONIDINE HYDROCHLORIDE

Post-LOE

clonidine hydrochloride

Teva

ANDAORALTABLET, EXTENDED RELEASE

Approved

Nov 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CLONIDINE HYDROCHLORIDE (clonidine hydrochloride) by Teva is 2 -adrenergic receptors in the brain. Approved for attention deficit hyperactivity disorder (adhd), adjunctive therapy to stimulant medications [see clinical studies ( )], adjunctive therapy to stimulant medications. First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

2 -adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.

Indications (2)

attention deficit hyperactivity disorder (ADHD)adjunctive therapy to stimulant medications

Worked on CLONIDINE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.